- Home
- MAIA
as 10-07-2025 3:30pm EST
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 56.3M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 636.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.40 - $3.48 | Next Earning Date: | 11-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MAIA Biotechnology Inc. (MAIA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Stan | MAIA | Director | Oct 1 '25 | Buy | $1.30 | 19,230 | $24,999.00 | 1,324,289 |
Latest MAIA Biotechnology Inc. News
MAIA Breaking Stock News: Dive into MAIA Ticker-Specific Updates for Smart Investing
Business Wire
3 months ago
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
TipRanks
4 months ago
MAIA Biotechnology, Roche sign supply agreement for cancer therapies
MT Newswires
4 months ago
Maia Biotechnology Signs Clinical Supply Deal With Roche; Shares Rise
Business Wire
4 months ago
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
Business Wire
4 months ago
MAIA Biotechnology to Present at BIO International Convention 2025
Benzinga
4 months ago
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
Business Wire
4 months ago
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
MT Newswires
4 months ago
Maia Biotechnology Says Ateganosine Treatment Extends Median Overall Survival in Lung Cancer Study
Compare MAIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MAIA MAIA Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.